Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 215

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline

Open access
Shah, Manish A., Kennedy, Erin B., Alarcon-Rozas, Ashley E., Alcindor, Thierry, Bartley, Angela N., Malowany, Aubrey Belk, Bhadkamkar, Nishin A., Deighton, Dana C., Janjigian, Yelena, Karippot, Asha, Khan, Uqba, King, Daniel A., Klute, Kelsey, Lacy, Jill, Lee, James J., Mehta, Rutika, Mukherjee, Sarbajit, Nagarajan, Arun, Park, Haeseong, Saeed, Anwaar, Semrad, Thomas J., Shitara, Kohei, Smyth, Elizabeth, Uboha, Nataliya V., Vincelli, Melani, Wainberg, Zev, Rajdev, Lakshmi · 2023 · Journal of Clinical Oncology

Abstract

PURPOSE: To develop recommendations involving targeted therapies for patients with advanced gastroesophageal cancer. METHODS: The American Society of Clinical Oncology convened an Expert Panel to conduct a systematic review of relevant studies and develop recommendations for clinical practice. RESULTS: Eighteen randomized controlled trials met the inclusion criteria for the systematic review. RECOMMENDATIONS: For human epidermal growth factor receptor 2 (HER2)–negative patients with gastric adenocarcinoma (AC) and programmed death-ligand 1 (PD-L1) combined positive score (CPS) ≥ 5, first-line therapy with nivolumab and chemotherapy (CT) is recommended. For HER2-negative patients with esophageal or gastroesophageal junction (GEJ) AC and PD-L1 CPS ≥ 5, first-line therapy with nivolumab and CT is recommended. First-line therapy with pembrolizumab and CT is recommended for HER2-negative patients with esophageal or GEJ AC and PD-L1 CPS ≥ 10. For patients with esophageal squamous cell carcinoma and PD-L1 tumor proportion score ≥ 1%, nivolumab plus CT, or nivolumab plus ipilimumab is recommended; for patients with esophageal squamous cell carcinoma and PD-L1 CPS ≥ 10, pembrolizumab plus CT is recommended. For patients with HER2-positive gastric or GEJ previously untreated, unresectable or metastatic AC, trastuzumab plus pembrolizumab is recommended, in combination with CT. For patients with advanced gastroesophageal or GEJ AC whose disease has progressed after first-line therapy, ramucirumab plus paclitaxel is recommended. For HER2-positive patients with gastric or GEJ AC who have progressed after first-line therapy, trastuzumab deruxtecan is recommended. In all cases, participation in a clinical trial is recommended as it is the panel's expectation that targeted treatment options for gastroesophageal cancer will continue to evolve. Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines .

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.22.02331

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 215

Metadata

Authors
Shah, M. A., Kennedy, E. B., Alarcon-Rozas, A. E., Alcindor, T., Bartley, A. N., Malowany, A. B., Bhadkamkar, N. A., Deighton, D. C., Janjigian, Y., Karippot, A., Khan, U., King, D. A., Klute, K., Lacy, J., Lee, J. J., Mehta, R., Mukherjee, S., Nagarajan, A., Park, H., Saeed, A., Semrad, T. J., Shitara, K., Smyth, E., Uboha, N. V., Vincelli, M., Wainberg, Z., & Rajdev, L.
Venue
Journal of Clinical Oncology
Published
2023-03-01
Volume
41
Issue
7
Pages
1470-1491
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W4313553529
Cited by
215
References
6
FWCI
22.36
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline. https://app.cochat.ai/papers/10.1200/jco.22.02331
The paper
Shah, M. A., Kennedy, E. B., Alarcon-Rozas, A. E., Alcindor, T., Bartley, A. N., Malowany, A. B., Bhadkamkar, N. A., Deighton, D. C., Janjigian, Y., Karippot, A., Khan, U., King, D. A., Klute, K., Lacy, J., Lee, J. J., Mehta, R., Mukherjee, S., Nagarajan, A., Park, H., . . . Rajdev, L. (2023). Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline. Journal of Clinical Oncology. https://doi.org/10.1200/jco.22.02331

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.